FDA approves extended-release painkiller

FDA approves extended-release painkiller
FDA approves extended-release painkiller

HealthDay News -- The FDA has approved oxycodone hydrochloride and naloxone hydrochloride extended release (Targiniq ER) as a long-term, around-the-clock treatment for severe pain when other therapies are ineffective or unavailable.

Targiniq ER has properties that are designed to deter abuse of the drug by snorting or injection, the FDA said in a news release.

It contains naloxone, which is designed to block the euphoric effects of oxycodone. The drug can still be abused by taking too many pills, the agency warned, stressing that an overdose could cause death. The drug is not meant for as-needed pain relief repeating its warning of the potential for abuse and addiction.

Targiniq ER was evaluated in a clinical study of 601 people with chronic lower back pain. The most common side effects were nausea and vomiting.

The agency said it is requiring the manufacturer to conduct additional post-marketing studies to assess the drug's risks of misuse, addiction, and abuse.

Loading links....
You must be a registered member of Clinical Advisor to post a comment.
close

Next Article in Web Exclusives

Sign Up for Free e-newsletters